Sytrinol (Polymethoxylated Flavones)

Sytrinol is a patented blend of polymethoxylated flavones (PMFs) — primarily tangeretin and nobiletin — derived from citrus peel, combined with palm tocotrienols. It lowers cholesterol and triglycerides by inhibiting hepatic lipid synthesis enzymes and reducing apolipoprotein B secretion.

Origin & History

Sytrinol is a branded ingredient consisting of polymethoxylated flavones (PMFs) extracted from the peels of citrus fruits, particularly oranges (Citrus sinensis) and grapefruits (Citrus paradisi). The PMFs are concentrated using solvent-based extraction methods and often combined with tocotrienols for enhanced cholesterol management effects.

Historical & Cultural Context

No traditional or historical medicinal use was identified for Sytrinol in the research, as it is a modern branded extract developed specifically for cholesterol management. Unlike whole citrus fruits used in traditional medicine, Sytrinol represents a concentrated, standardized preparation of specific citrus peel compounds.

Health Benefits

• Reduces total cholesterol by 20-30% in hypercholesterolemic adults (Strong evidence from 12-week RCT, n=120)
• Lowers LDL cholesterol by 19-27% (Strong evidence from double-blind RCT)
• Decreases triglycerides by 24-34% (Strong evidence from clinical trials)
• Reduces apolipoprotein B levels by 21% (Moderate evidence from one RCT)
• Maintains or slightly increases HDL cholesterol levels (Moderate evidence from clinical studies)

How It Works

Sytrinol's polymethoxylated flavones — tangeretin and nobiletin — suppress hepatic de novo lipogenesis by downregulating sterol regulatory element-binding protein-1c (SREBP-1c) and inhibiting HMG-CoA reductase activity, reducing endogenous cholesterol synthesis. The PMFs also decrease microsomal triglyceride transfer protein (MTP) activity, impairing VLDL assembly and apolipoprotein B-100 secretion from hepatocytes. Palm tocotrienols in the formula provide complementary HMG-CoA reductase suppression via post-transcriptional mechanisms distinct from statin pathways.

Scientific Research

The primary clinical evidence for Sytrinol comes from a randomized controlled trial (PMID: 17985810) that included two open-label studies (n=10 each) and one 12-week double-blind RCT (n=120) in hypercholesterolemic adults. The combination of 270 mg citrus PMFs plus 30 mg tocotrienols showed significant lipid improvements versus placebo.

Clinical Summary

A 12-week randomized, double-blind, placebo-controlled trial (n=120) in hypercholesterolemic adults demonstrated that Sytrinol at 300 mg/day reduced total cholesterol by 20–30%, LDL cholesterol by 19–27%, and triglycerides by 24–34% compared to baseline. Apolipoprotein B levels declined by approximately 21%, reflecting reduced atherogenic particle output. Evidence quality is strong for lipid-lowering endpoints given the RCT design, though long-term cardiovascular outcome data beyond 12 weeks remain limited. Independent replication in larger, multi-center trials is needed to confirm magnitude of effect across diverse populations.

Nutritional Profile

Sytrinol is a patented, standardized extract composed primarily of polymethoxylated flavones (PMFs) derived from citrus peel (primarily sweet orange, Citrus sinensis) combined with tocotrienols from palm fruit (Elaeis guineensis). Key bioactive compounds include: Tangeretin (primary PMF, ~30-40% of PMF fraction), Nobiletin (~20-30% of PMF fraction), Sinensetin and other minor PMFs (~10-15%), and mixed tocotrienols (alpha, beta, gamma, delta isoforms, ~20-30% of total extract). Typical standardized dosage used in clinical trials is 300 mg/day total extract. PMF concentration in commercial Sytrinol is standardized to approximately 50-60% total polymethoxylated flavones by weight. Tocotrienol content is approximately 40-50% of extract weight. Sytrinol contains no significant macronutrients (protein, fat, carbohydrate), dietary fiber, or conventional vitamins and minerals at functional doses. Bioavailability: PMFs are lipophilic compounds with moderate oral bioavailability; absorption is enhanced when taken with dietary fat. Tangeretin and nobiletin undergo hepatic first-pass metabolism via CYP450 enzymes (primarily CYP3A4) and undergo enterohepatic recirculation. Tocotrienols exhibit superior bioavailability compared to tocopherols due to distinct hepatic metabolism. Half-life of PMFs is estimated at 4-6 hours. The synergistic combination of PMFs and tocotrienols in Sytrinol is proposed to enhance lipid-modulating efficacy beyond either component alone, primarily through inhibition of HMG-CoA reductase and ACAT (acyl-CoA:cholesterol acyltransferase) activity.

Preparation & Dosage

Clinically studied dosage: 270 mg citrus PMFs standardized to polymethoxylated flavones plus 30 mg tocotrienols daily, divided into doses with meals. Duration: 4-12 weeks as studied in hypercholesterolemic subjects. Available in powder/capsule forms. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Tocotrienols, Red Yeast Rice, Plant Sterols, Omega-3 Fatty Acids, Artichoke Leaf Extract

Safety & Interactions

Sytrinol is generally well tolerated in short-term studies up to 12 weeks, with no significant adverse events reported at the standard 300 mg/day dose. Because PMFs are metabolized via CYP3A4 and CYP1A2 hepatic enzymes, caution is warranted when combining Sytrinol with statins, warfarin, or other CYP450-substrate drugs, as competitive inhibition may alter drug plasma levels. Pregnant and breastfeeding women should avoid Sytrinol due to insufficient safety data, and individuals with citrus allergies should consult a physician before use. Those already taking lipid-lowering medications should seek medical supervision to monitor for additive hypocholesterolemic effects.